Selected research
Industry Research
Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Research Report 2026
Market perspective
The global Tumor Necrosis Factor Receptor Superfamily Member 1A market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 1A is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily Member 1A is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A include Addex Therapeutics Ltd, G&E Herbal Biotechnology Co., Ltd., Inflamalps SA, Polaris Pharmaceuticals, Inc. and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tumor Necrosis Factor Receptor Superfamily Member 1A market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Necrosis Factor Receptor Superfamily Member 1A Market by Company
Addex Therapeutics Ltd
G&E Herbal Biotechnology Co., Ltd.
Inflamalps SA
Polaris Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Type
EYS-606
LY-3232094
SRT-100
Others
Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Application
Multiple Sclerosis
Melanoma
Genital Warts
Psoriasis
Others
Tumor Necrosis Factor Receptor Superfamily Member 1A Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 1A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 1A and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 1A.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 1A manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tumor Necrosis Factor Receptor Superfamily Member 1A by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tumor Necrosis Factor Receptor Superfamily Member 1A in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- EYS-606
- LY-3232094
- SRT-100
- Others
Applications
- Multiple Sclerosis
- Melanoma
- Genital Warts
- Psoriasis
- Others
Companies covered
- Addex Therapeutics Ltd
- G&E Herbal Biotechnology Co., Ltd.
- Inflamalps SA
- Polaris Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size (2021-2032)
- 2.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (2021-2032)
- 2.2.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Average Price (2021-2032)
- 2.3 Tumor Necrosis Factor Receptor Superfamily Member 1A by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 EYS-606
- 2.3.3 LY-3232094
- 2.3.4 SRT-100
- 2.3.5 Others
- 2.4 Tumor Necrosis Factor Receptor Superfamily Member 1A by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Multiple Sclerosis
- 2.4.3 Melanoma
- 2.4.4 Genital Warts
- 2.4.5 Psoriasis
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue of Manufacturers (2021-2026)
- 3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Average Price by Manufacturers (2021-2026)
- 3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A, Product Type & Application
- 3.8 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 1A, Established Date
- 3.9 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Addex Therapeutics Ltd
- 4.1.1 Addex Therapeutics Ltd Company Information
- 4.1.2 Addex Therapeutics Ltd Business Overview
- 4.1.3 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Addex Therapeutics Ltd Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
- 4.1.5 Addex Therapeutics Ltd Recent Developments
- 4.2 G&E Herbal Biotechnology Co., Ltd.
- 4.2.1 G&E Herbal Biotechnology Co., Ltd. Company Information
- 4.2.2 G&E Herbal Biotechnology Co., Ltd. Business Overview
- 4.2.3 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 G&E Herbal Biotechnology Co., Ltd. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
- 4.2.5 G&E Herbal Biotechnology Co., Ltd. Recent Developments
- 4.3 Inflamalps SA
- 4.3.1 Inflamalps SA Company Information
- 4.3.2 Inflamalps SA Business Overview
- 4.3.3 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Inflamalps SA Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
- 4.3.5 Inflamalps SA Recent Developments
- 4.4 Polaris Pharmaceuticals, Inc.
- 4.4.1 Polaris Pharmaceuticals, Inc. Company Information
- 4.4.2 Polaris Pharmaceuticals, Inc. Business Overview
- 4.4.3 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Polaris Pharmaceuticals, Inc. Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
- 4.4.5 Polaris Pharmaceuticals, Inc. Recent Developments
- 4.5 GlaxoSmithKline Plc
- 4.5.1 GlaxoSmithKline Plc Company Information
- 4.5.2 GlaxoSmithKline Plc Business Overview
- 4.5.3 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 1A Product Portfolio
- 4.5.5 GlaxoSmithKline Plc Recent Developments
5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Scenario by Region
- 5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region: 2021-2032
- 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region: 2021-2026
- 5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Region: 2027-2032
- 5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2021-2032
- 5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2021-2026
- 5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Region: 2027-2032
- 5.4 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Facts & Figures by Country
- 5.4.1 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
- 5.4.3 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Facts & Figures by Country
- 5.5.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
- 5.5.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Facts & Figures by Country
- 5.7.1 South America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
- 5.7.3 South America Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021-2032)
- 6.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Type (2021-2032)
- 6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Type (2021-2032)
- 6.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Type (2021-2032)
- 6.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021-2032)
- 7.1.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Market Share by Application (2021-2032)
- 7.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue by Application (2021-2032)
- 7.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Revenue Market Share by Application (2021-2032)
- 7.3 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Value Chain Analysis
- 8.1.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Production Mode & Process
- 8.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Distributors
- 8.2.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Customers
9 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Analyzing Market Dynamics
- 9.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Trends
- 9.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Drivers
- 9.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Opportunities and Challenges
- 9.4 Tumor Necrosis Factor Receptor Superfamily Member 1A Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst